Adoptive immunotherapy for cancer: building on success

Adoptive immunotherapy for cancer: building on success

Adoptive cell transfer after host preconditioning by lymphodepletion represents an important advance in cancer immunotherapy. Here, we describe how a lymphopaenic environment enables tumour-reactive T cells to destroy large burdens of metastatic tumour and how the state of differentiation of the ado...

Full description

Saved in:
Bibliographic Details
Published in:Nature Reviews: Immunology Vol. 6; no. 5; pp. 383 - 393
Main Authors: Gattinoni, Luca, Restifo, Nicholas P, Powell, Daniel J, Rosenberg, Steven A
Format: Journal Article
Language:English
Published: England Nature Publishing Group 01-05-2006
Subjects:
Animals
Antigens
Cancer therapies
Cancer vaccines
Cells
Chemotherapy
Cytokines
Humans
Immune system
Immunology
Immunotherapy
Immunotherapy, Adoptive - methods
Lymphocytes
Melanoma
Neoplasms - immunology
Neoplasms - therapy
T-Lymphocyte Subsets - transplantation
Tumors
Vaccines
United States > US
Maryland
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Adoptive cell transfer after host preconditioning by lymphodepletion represents an important advance in cancer immunotherapy. Here, we describe how a lymphopaenic environment enables tumour-reactive T cells to destroy large burdens of metastatic tumour and how the state of differentiation of the adoptively transferred T cells can affect the outcome of treatment. We also discuss how the translation of these new findings might further improve the efficacy of adoptive cell transfer through the use of vaccines, haematopoietic-stem-cell transplantation, modified preconditioning regimens, and alternative methods for the generation and selection of the T cells to be transferred.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
These authors contributed equally to this work. National Cancer Institute, National Institutes of Health, Mark O. Hatfield Clinical Research Center, Room 3-5762, 10 Center Drive, Bethesda, Maryland 20892-1201, USA.
ISSN:1474-1733
1474-1741
1365-2567
DOI:10.1038/nri1842